Kite to expand production capabilities with new oncology facility

Written by Freya Leask

The 20-acre site will produce innovative cell therapies for patients with oncology, such as Yescarta®.

Kite, a Gilead company (CA, USA), have announced plans for a new 20-acre state-of-the-art manufacturing facility in MD, USA to expand their manufacturing capability. The new site will manufacture CAR-T based therapies, which require complex and multi-step-processes, such as Yescarta® (axicabtagene ciloleucel), Kite’s first commercially available CAR T cancer therapy.

“This new facility in Frederick County builds on our substantial technical capabilities and rapid progress in making personalized CAR T and TCR cell therapies for people with cancer. As we advance our industry-leading cell therapy pipeline and seek to help a growing number of people with cancer, expanding and investing in our manufacturing capabilities is essential,” said Tim Moore, Executive Vice President of Technical Operations at Kite.

“With the Frederick County site, we will have the opportunity to build and design the facility tailored to our own innovative processes and with state-of-the-art features that will enable us to meet the future needs for cell therapies.”